Schizophrenia and Psychosis

A new study in JAMA Neurology finds that the use of antipsychotic drugs more than doubled the risk of death in patients with Parkinson’s...

Over the past two months, Ronald Pies and Allen Frances, in response to a post I had written, wrote several blogs that were meant to serve as an “evidence-based” defense of the long-term use of antipsychotics. As I read their pieces, I initially focused on that core argument they were presenting, but second time through, the aha moment arrived for me. Their blogs, when carefully parsed, make a compelling case that their profession, in their use of antipsychotics as a treatment for multiple psychotic disorders, has done great harm, and continues to do so today.

A team from Sweden's Karolinska Institute and Britain's University College of London found, in a study of 1.3 million people in Sweden's national register,...

A new study out of the University of Manchester found that personalized exercise programs reduced the symptoms for young people suffering from their first episode of psychosis. Researchers also conducted an accompanying qualitative analysis and found that the participants experienced improved mental health, confidence, and a sense of achievement and felt that autonomy and social support were critical to their success.

From the Daily Beast: "Amphetamines come with a host of negative side effects, most commonly insomnia and irregular heartbeat. But in less common cases, the...

A new study to be published in the next issue of Schizophrenia Research examines patients suffering from a first-episode of psychosis who stop taking any antipsychotic drugs. The researchers attempt to identify variables that can serve as predictors of the successful discontinuation of antipsychotics. They find, for example, that those who discontinue the drugs have, on average, the same outcomes as those who stay on them, and that those who have better social integration are more likely to discontinue without relapse.

Columnist Nev Jones writes about the lack of adequate care for people in the US experiencing a first-episode of psychosis. “Evidence-based (or informed) psychotherapies...

What is schizophrenia? According to the website of the National Institute of Mental Health (NIMH), schizophrenia is a chronic, severe, incurable, and disabling brain disorder that affects about 1% of Americans today. Its cause is unknown but most experts assume it is genetic. According to E. Fuller Torrey, the founder and Executive Director of the Stanley Medical Research Institute and a high-profile schizophrenia researcher, “schizophrenia is caused by changes in the brain and ... these can be measured by changes in both brain structure and brain function. … Schizophrenia is thus a disease of the brain in exactly the same sense that Parkinson’s disease, multiple sclerosis, epilepsy, and Alzheimer’s disease are diseases of the brain.” Behind this confident rhetoric lies a heated controversy.

Vermont Governor Shumlin recently suggested a change to state law that would accelerate the process under which a person could be forced to take antipsychotic drugs against her will. The House Human Services Committee reviewed this proposal and I was asked to testify. What follows are my comments.

There is a substantial body of evidence suggesting that not getting enough omega-3 fatty acids in your diet may be connected to a diverse array of psychiatric symptoms. In a new study published this month, psychiatrist Robert McNamara and Erik Messamore provide an overview of the evidence and call for screening of omega-3 deficiency in people experiencing symptoms associated with ADHD, depression, mood disorders, and psychosis.

A pathbreaking new study out of Finland suggests that early intervention programs for youth experiencing psychotic-like symptoms may see the greatest improvement when treatment works within the home rather than in a hospital setting. The research, to be published in next month’s issue of Psychiatry Research, found greater improvement in functioning, depression, and hopelessness among teens in a new need-adapted Family and Community oriented Integrative Treatment Model (FCTM) program.

A study published in this month’s issue of the Social Psychiatry and Psychiatric Epidemiology found that perceived discrimination related to minority status may precede...

Benedict Carey of the New York Times reports on the success of new schizophrenia and psychosis programs that provide family counseling and job and...

"Eleanor Longden started hearing voices when she was 18. She was drugged and hospitalised, then told she was schizophrenic. A psychiatrist even told her...

MIA contributor Jonathan Leo, writing for Slate, weighs in on the research that claims to have discovered a genetic basis for schizophrenia. “We now...

Last week, the headlines blared: "Schizophrenia breakthrough as genetic study reveals link to brain changes!"  We heard that our best hope for treating “schizophrenia” is to understand it at a genetic level, and that this new breakthrough would get us really started on that mission, as it showed how a genetic variation could lead to the more intense pruning of brain connections, which is often seen in those diagnosed with schizophrenia.  “For the first time, the origin of schizophrenia is no longer a complete black box,” said one (while admitting that "it's still early days").  The acting director of the National Institute of Mental Health (NIMH) described the study as “a crucial turning point in the fight against mental illness.” But is all this hype justified?

In a study published yesterday, researchers from the Nippon Medical School in Tokyo bring attention to a condition known as neuroleptic-induced deficit syndrome (NIDS)...

Dutch psychiatrist and epidemiologist, Jim van Os, has renewed his call to drop schizophrenia as a disease classification. “Several recent papers by different authors...

Four weeks ago, after I wrote a blog about a study that concluded there was no good evidence that antipsychotics improved long-term outcomes for people diagnosed with schizophrenia, I was cc’d on an email that had been sent to a number of “thought leaders” about what I had written. At least as I read the email, it put me into the usual pigeonhole for critics of psychiatric drugs: I apparently was globally “against” medications, and I had displayed a type of simplistic “categorical” thinking. All of this led to my having an email exchange with Allen Frances, and his laying out, in his opinion, the considerable "collateral damage" my writings had done.

“Overall, this study showed that the information and awareness campaign had almost no significant effects on the general public's attitudes toward people affected by either schizophrenia or depression,” the researchers, led by German medical sociologist Anna Makowski, wrote. “One could assume that deeply rooted convictions cannot be modified by rather time-limited and general activities targeted at the public.”

In recent months, two teams of researchers in the UK and the US published complementary findings about the epigenetic origins of schizophrenia that have scientific communities who indulge in ‘genetic conspiracy theories’ abuzz. While these results are intriguing, and no doubt involve pathbreaking research methodologies, this line of thought represents a decontextualized understanding both of the symptoms that are typically associated with schizophrenia, and their causes.

Plaintiffs allege that Bristol-Myers Squibb and Otsuka Pharmaceutical failed to warn doctors and patients about the risk for compulsive behaviors when taking the atypical...

According to new research by Joanna Moncrieff and Sebastião Viola, mental health problems have become the leading cause of disability claims in the UK. While the overall number of claims for other conditions has decreased by 35%, claims related to “mental disorders” have increased 103% since 1995.

In this month’s issue of Psychological Medicine, researchers from King’s College London found evidence for associations between different types of childhood adversity and specific symptoms associated with psychosis. As current categorical approaches to psychosis and schizophrenia diagnoses come under increasing scrutiny, this study adds support to sociological and psychological theories and treatments.

The Boston Globe reports on the discovery of a newly recognized neurological disease, anti-NMDA receptor encephalitis. The disease is believed to be caused when the body’s immune system attacks proteins in the brain associated with the communication of neurons.